Artiva Biotherapeutics, Inc.
ARTV- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001817241
In the last 90 days, Artiva Biotherapeutics, Inc. insiders filed 5 open-market purchases and 7 sales; 72 institutions reported holding it in 13F filings for Q2 2026, worth $391.6M in total; Viking Global Investors is the only superinvestor holding it.
13F holders, Q1 2026
Institutional positions in Artiva Biotherapeutics, Inc. as of Mar 31, 2026. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 40
- +7 vs. Q4 2025
- Shares held
- 16.8M
- +124.3K (+0.7%) vs. Q4 2025
- Total value
- $108.4M
- +$36.7M (+51.2%) vs. Q4 2025
- New holders
- 12
- 3 more added
- Sold out
- 5
- 12 more reduced
1 institution that held it in Q4 2025 haven't filed for Q1 2026 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q4 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ARTV on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 72 | $391.6M |
| Q1 2026 | 40 | $108.4M |
| Q4 2025 | 34 | $72.7M |
| Q3 2025 | 40 | $52.1M |
| Q2 2025 | 48 | $27.9M |
| Q1 2025 | 53 | $62.8M |
| Q4 2024 | 57 | $213.2M |
| Q3 2024 | 49 | $319.4M |
| Q2 2024 | 0 | $0 |
| Q1 2024 | 0 | $0 |
| Q4 2023 | 0 | $0 |
| Q3 2023 | 0 | $0 |
| Q2 2023 | 0 | $0 |
| Q1 2023 | 0 | $0 |
| Q4 2022 | 0 | $0 |
| Q3 2022 | 0 | $0 |
| Q2 2022 | 0 | $0 |
| Q1 2022 | 0 | $0 |
| Q4 2021 | 0 | $0 |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q1 2026
Shares, value and share of portfolio for each institution holding Artiva Biotherapeutics, Inc.; share changes are against Q4 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Ra Capital Management, L.P. | 9,853,302 | $63.5M | 0.67% | 00.0% | Unchanged |
| 5AM Venture Management, LLC | 2,353,304 | $15.2M | 4.21% | 00.0% | Unchanged |
| VR Adviser, LLC | 1,609,569 | $10.4M | 0.39% | 00.0% | Unchanged |
| venBio Partners LLC | 531,337 | $3.42M | 1.22% | −117,170−18.1% | Reduced |
| Franklin Resources Inc | 520,327 | $3.35M | 0.00% | 00.0% | Unchanged |
| Revelation Capital Management, LLC | 299,311 | $1.93M | 2.86% | 00.0% | Unchanged |
| BlackRock, Inc. | 213,388 | $1.37M | 0.00% | +850+0.4% | Added |
| Vanguard Capital Management LLC | 207,686 | $1.34M | 0.00% | +207,686 | New |
| Wellington Management Group LLP | 194,108 | $1.25M | 0.00% | 00.0% | Unchanged |
| Propel Bio Management, LLC | 146,369 | $949.8K | 0.60% | +146,369 | New |
| Millennium Management LLC | 123,270 | $793.9K | 0.00% | −93,827−43.2% | Reduced |
| Two Sigma Investments, LP | 115,041 | $740.9K | 0.00% | −29,823−20.6% | Reduced |
| Geode Capital Management, LLC | 101,695 | $655.5K | 0.00% | +578+0.6% | Added |
| Alyeska Investment Group, L.P. | 100,000 | $644.0K | 0.00% | 00.0% | Unchanged |
| Renaissance Technologies LLC | 80,038 | $515.4K | 0.00% | −36,162−31.1% | Reduced |
| Jane Street Group, LLC | 39,496 | $254.4K | 0.00% | −1,175−2.9% | Reduced |
| State Street Corp | 35,824 | $230.7K | 0.00% | 00.0% | Unchanged |
| Bridgeway Capital Management, LLC | 35,000 | $225.4K | 0.00% | 00.0% | Unchanged |
| Vanguard Fiduciary Trust Co | 32,810 | $211.3K | 0.00% | +32,810 | New |
| Panagora Asset Management Inc | 30,702 | $197.7K | 0.00% | +30,702 | New |
| Velan Capital Investment Management LP | 25,000 | $161.0K | 0.10% | +25,000 | New |
| Simplify Asset Management Inc. | 23,230 | $149.6K | 0.00% | +23,230 | New |
| Sanctuary Advisors, LLC | 21,581 | $139.0K | 0.00% | +21,581 | New |
| Bailard, Inc. | 20,700 | $133.3K | 0.00% | +20,700 | New |
| Dimensional Fund Advisors LP | 20,370 | $131.2K | 0.00% | +20,370 | New |
| XTX Topco Ltd | 20,270 | $130.5K | 0.00% | +20,270 | New |
| Morgan Stanley | 16,377 | $105.5K | 0.00% | −10,695−39.5% | Reduced |
| Citadel Advisors LLC | 15,870 | $102.2K | 0.00% | +15,870 | New |
| Northern Trust Corp | 12,208 | $78.6K | 0.00% | +12,208 | New |
| Goldman Sachs Group Inc | 11,465 | $73.8K | 0.00% | −595−4.9% | Reduced |
| Omers Administration Corp | 11,400 | $73.4K | 0.00% | −9,700−46.0% | Reduced |
| Russell Investments Group, Ltd. | 5,491 | $35.4K | 0.00% | 00.0% | Unchanged |
| FMR LLC | 3,529 | $22.7K | 0.00% | −29−0.8% | Reduced |
| UBS Group AG | 1,527 | $9.83K | 0.00% | −35,346−95.9% | Reduced |
| Wells Fargo & Company | 1,500 | $9.66K | 0.00% | 00.0% | Unchanged |
| Mark Sheptoff Financial Planning, LLC | 400 | $4.24K | 0.00% | 00.0% | Unchanged |
| BNP Paribas Arbitrage, SA | 542 | $3.49K | 0.00% | 00.0% | Unchanged |
| JPMorgan Chase & Co | 223 | $1.22K | 0.00% | +36+19.3% | Added |
| Royal Bank of Canada | 188 | $1.00K | 0.00% | −151−44.5% | Reduced |
| Advisor Group Holdings, Inc. | 18 | $116 | 0.00% | −14−43.8% | Reduced |
| Marshall Wace, LLP | 0 | $0 | 0.00% | −79,559−100.0% | Sold out |
| Scientech Research LLC | 0 | $0 | 0.00% | −27,757−100.0% | Sold out |
| Prelude Capital Management, LLC | 0 | $0 | 0.00% | −10,691−100.0% | Sold out |
| Tower Research Capital LLC (TRC) | 0 | $0 | 0.00% | −1,103−100.0% | Sold out |
| Bank of America Corp | 0 | $0 | 0.00% | −113−100.0% | Sold out |
| Vanguard Group Inc | – | – | – | – | Not filed |